NRX Pharmaceuticals Inc
NASDAQ:NRXP

Watchlist Manager
NRX Pharmaceuticals Inc Logo
NRX Pharmaceuticals Inc
NASDAQ:NRXP
Watchlist
Price: 1.865 USD -8.58% Market Closed
Market Cap: $52.4m

Net Margin

-15 727.7%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-15 727.7%
=
Net Income
$-38.1m
/
Revenue
$242k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-15 727.7%
=
Net Income
$-38.1m
/
Revenue
$242k

Peer Comparison

Country Company Market Cap Net
Margin
US
NRX Pharmaceuticals Inc
NASDAQ:NRXP
53.4m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1.1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
564.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
287.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
294.9B USD
Loading...
CH
Novartis AG
SIX:NOVN
229.6B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
215B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
153.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
98.9B EUR
Loading...

Market Distribution

Lower than 97% of companies in the United States of America
Percentile
3rd
Based on 15 072 companies
3rd percentile
-15 727.7%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

NRX Pharmaceuticals Inc
Glance View

Market Cap
52.4m USD
Industry
Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB). Its ZYESAMI (aviptadil) is an investigational drug for COVID-19-related respiratory failure. The firm has completed a Phase IIb/III clinical study in patients with acute respiratory failure in COVID-19.

NRXP Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-15 727.7%
=
Net Income
$-38.1m
/
Revenue
$242k
What is NRX Pharmaceuticals Inc's current Net Margin?

The current Net Margin for NRX Pharmaceuticals Inc is -15 727.7%, which is in line with its 3-year median of -15 727.7%.

How has Net Margin changed over time?

Over the last 0 months, NRX Pharmaceuticals Inc’s Net Margin has decreased from -15 727.7% to -15 727.7%. During this period, it reached a low of -15 727.7% on Oct 30, 2025 and a high of -15 727.7% on Oct 30, 2025.

Back to Top